An update on the current management of hyponatremia

Minerva Medica

Volumn 103, Issue 4, 2012, Pages 279-291

  Lindner, G ^a   Schwarz, C ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Electrolytes; Hyponatremia; Vasopressins

Indexed keywords

CONIVAPTAN; DEMECLOCYCLINE; LIXIVAPTAN; PLACEBO; RINGER LACTATE SOLUTION; SATAVAPTAN; TOLVAPTAN; UREA; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; CARDIOPLEGIA; CREATININE BLOOD LEVEL; DEHYDRATION; DIZZINESS; EXTRACELLULAR SPACE; FAINTNESS; HOSPITAL PATIENT; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; MOLECULAR MECHANICS; POLYDIPSIA; PSEUDOHYPONATREMIA; REVIEW; RISK FACTOR; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM INTAKE;

BODY WATER; DISEASE MANAGEMENT; HUMANS; HYPONATREMIA; KIDNEY; RECEPTORS, VASOPRESSIN; SODIUM; VASOPRESSINS;

EID: 84867406735     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Rose BD. Clinical physiology of acid-base and electrolyte disorders. 5 ed. New York: Mcgraw-Hill; 2001.
2. Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med 2000;342:1493-9. (Pubitemid 30318274)
3. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-9. (Pubitemid 30340505)
4. Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985;102:164-8. (Pubitemid 15157162)
5. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010;170:294-302.
6. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122:857-65.
7. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in Hospitalized Cancer Patients and Its Impact on Clinical Outcomes. Am J Kidney Dis 2012;59:222-8.
8. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Moinar MZ et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012;125:677-84.
9. Scherz N, Labarère J, Méan M, Ibrahim S, Fine MJ, Aujesky D. Prognostic importance of hyponatremia in patients with acute pulmonary embolism. Am J Respir Crit Care Med 2010;182:1178-83.
10. Funk GC, Lindner G, Druml W, Metnitz B, Schwarz C, Bauer P et al. Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med 2010;36:304-11.
11. Stelfox HT, Ahmed SB, Khandwala F, Zygun D, Shahpori R, Laupland K. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units. Crit Care 2008;12:R162.
12. Stelfox HT, Ahmed SB, Zygun D, Khandwala F, Laupland K. Characterization of intensive care unit acquired hyponatremia and hypernatremia following cardiac surgery. Can J Anaesth 2010;57:650-8.
13. Lee CT, Guo HR, Chen JB. Hyponatremia in the emergency department. Am J Emerg Med 2000;18:264-8.
14. Arampatzis S, Exadaktylos A, Buhl D, Zimmermann H, Lindner G. Dysnatraemias in the emergency room: Undetected, untreated, unknown? Wien Klin Wochenschr 2012;124:181-3.
15. Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt BA et al. Hyponatremia among runners in the Boston Marathon. N Engl J Med 2005;352:1550-6.
16. Edelman IS, Leibman J, O'Meara MP, Birkenfeld LW. Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest 1958;37:1236-56.
17. Halperin ML, Kamel KS, Goldstein MB. Fluid, electrolyte, and acid-base physiology: A problem based approach. 4th ed. Philadelphia, PA: Saunders ElSevier; 2009.
18. Desmond J. Serum osmolality and plasma electrolytes in patients who develop dilutional hyponatremia during transurethral resection. Can J Surg 1970;13:116-21.
19. Lindner G, Kneidinger N, Holzinger U, Druml W, Schwarz C. Tonicity balance in patients with hypernatremia acquired in the intensive care unit. Am J Kidney Dis 2009;54:674-9.
20. Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ 2002;166:1056-62. (Pubitemid 34304651)
21. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006;44:1535-42. (Pubitemid 44953659)
22. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981;305:263-6. (Pubitemid 11087371)
23. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982;96:413-7. (Pubitemid 12139861)
24. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-67. (Pubitemid 16127402)
25. Goldberg A, Hammerman H, Petcherski S, Nassar M, Zdorovyak A, Yalonetsky S et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 2006;166:781-6.
26. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-26.
27. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-60. (Pubitemid 43668830)
28. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-72. (Pubitemid 46789896)
29. Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am 2010;21:339-52.
30. Green HH, Harrington AR, Valtin H. On the role of antidiuretic hormone in the inhibition of acute water diuresis in adrenal insufficiency and the effects of gluco- and mineralocorticoids in reversing the inhibition. J Clin Invest 1970;49:1724-36.
31. Hawken ER, Crookall JM, Reddick D, Millson RC, Milev R, Delva N. Mortality over a 20-year period in patients with primary polydipsia associated with schizophrenia: a retrospective study. Schizophr Res 2009;107:128-33.
32. Robertson GL, Aycinena P, Zerbe RL. Neurogenic disorders of osmoregulation. Am J Med 1982;72:339-53. (Pubitemid 12191851)
33. Davison JM, Shiells EA, Philips PR, Lindheimer MD. Influence of humoral and volume factors on altered osmoregulation of normal human pregnancy. Am J Physiol 1990;258:F900-7. (Pubitemid 20155502)
34. Lien YH, Shapiro JI. Hyponatremia: clinical diagnosis and management. Am J Med 2007;120:653-8. (Pubitemid 47176511)
35. Roscoe JM, Halperin ML, Rolleston FS, Goldstein MB. Hyperglycemia-induced hyponatremia: metabolic considerations in calculation of serum sodium depression. Can Med Assoc J 1975;112:452-3.
36. Croal BL, Blake AM, Johnston J, Glen AC, O'Reilly DS. Absence of relation between hyponatraemia and hypothyroidism. Lancet 1997;350:1402.
37. Kim JT, Park YH, Chang YE, Byon HJ, Kim HS, Kim CS et al. The effect of cardioplegic solution-induced sodium concentration fluctuation on postoperative seizure in pediatric cardiac patients. Ann Thorac Surg 2011;91:1943-8.
38. Lindner G. Isoosmotic hyponatremia after HTK-induced cardioplegia. Ann Thorac Surg 2012,93:692-3; author reply 3.
39. Lien YH, Shapiro JI, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J Clin Invest 1991;88:303-9.
40. Noakes TD, Sharwood K, Speedy D, Hew T, Reid S, Dugas J et al. Three independent biological mechanisms cause exercise-associated hyponatremia: evidence from 2,135 weighed competitive athletic performances. Proc Natl Acad Sci U S A 2005;102:18550-5. (Pubitemid 43011263)
41. Schrier RW. Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol 2010;6:185.
42. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71 e1-8.
43. Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010;25:554-63.
44. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010;5:275-80.
45. Hoorn EJ, Rivadeneira F, van Meurs JB, Ziere G, Stricker BH, Hofman A et al. Mild hyponatremia as a risk factor for fractures: The Rotterdam Study. J Bone Miner Res 2011;26:1822-8.
46. Sjoblom E, Hojer J, Ludwigs U, Pirskanen R. Fatal hyponatraemic brain oedema due to common gastroenteritis with accidental water intoxication. Intensive Care Med 1997;23:348-50. (Pubitemid 27130004)
47. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120:S1-21.
48. Nzerue CM, Baffoe-Bonnie H, You W, Falana B, Dai S. Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc 2003;95:335-43. (Pubitemid 37101953)
49. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999;281:2299-304. (Pubitemid 29289822)
50. Sterns RH. Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases. Ann Intern Med 1987;107:656-64. (Pubitemid 18041860)
51. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994;4:1522-30.
52. Brunner JE, Redmond JM, Haggar AM, Kruger DF, Elias SB. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. Ann Neurol 1990;27:61-6. (Pubitemid 20031359)
53. Tanneau RS, Henry A, Rouhart F, Bourbigot B, Garo B, Mocquard Y et al. High incidence of neurologic complications following rapid correction of severe hyponatremia in polydipsic patients. J Clin Psychiatry 1994;55:349-54. (Pubitemid 24286487)
54. Adrogue HJ, Madias NE. Aiding fluid prescription for the dysnatremias. Intensive Care Med 1997;23:309-16. (Pubitemid 27129997)
55. Barsoum NR, Levine BS. Current prescriptions for the correction of hyponatraemia and hypernatraemia: are they too simple? Nephrol Dial Transplant 2002;17:1176-80. (Pubitemid 34812060)
56. Nguyen MK, Kurtz I. A new quantitative approach to the treatment of the dysnatremias. Clin Exp Nephrol 2003;7:125-37. (Pubitemid 36898690)
57. Lindner G, Schwarz C, Kneidinger N, Kramer L, Oberbauer R, Druml W. Can we really predict the change in serum sodium levels? An analysis of currently proposed formulae in hypernatraemic patients. Nephrol Dial Transplant 2008;23:3501-8.
58. Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2007;2:1110-7.
59. Noakes T. Fluid replacement during marathon running. Clin J Sport Med 2003;13:309-18. (Pubitemid 37210527)
60. Robertson GL. Posterior pituitary. Felig P, Baxter J, Broadus A, Frohman L, editors. Endocrinology and metabolism. New York: McGraw Hill; 1986. p. 338-85.
61. Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis 2010;56:325-37.
62. Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975;83:654-6.
63. Dousa TP, Wilson DM. Effects of demethylchlortetracycline on cellular action of antidiuretic hormone in vitro. Kidney Int 1974;5:279-84.
64. Soudan K, Qunibi W. Severe Hypernatremia Following Treatment of the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Am J Med Sci 2012.
65. Lindner G, Schwarz C, Funk GC. Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients. Nephrol Dial Transplant 2012;27:962-7.
66. Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012;7:742-7.
67. Decaux G, Andres C, Gankam Kengne F, Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care 2010;14.R184.
68. Lindner G, Funk GC, Lassnigg A, Mouhieddine M, Ahmad SA, Schwarz C et al. Intensive care-acquired hypernatremia after major cardiothoracic surgery is associated with increased mortality. Intensive Care Med 2010;36:1718-23.
69. Lindner G, Funk GC, Schwarz C, Kneidinger N, Raider A, Schneeweiss B et al. Hypernatremia in the critically ill is an independent risk factor for mortality. Am J Kidney Dis 2007;50:952-7. (Pubitemid 350122812)
70. Kleinschmidt-DeMasters BK, Norenberg MD. Rapid correction of hyponatremia causes demyelination: relation to central pontine myelinolysis. Science 1981;211:1068-70. (Pubitemid 11131546)
71. Sterns RH, Riggs JE, Schochet SS, Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986;314:1535-42. (Pubitemid 16114683)
72. Sterns RH, Thomas DJ, Herndon RM. Brain dehydration and neurologic deterioration after rapid correction of hyponatremia. Kidney Int 1989;35:69-75. (Pubitemid 19047425)
73. Gankam Kengne F, Soupart A, Pochet R, Brion JP, Decaux G. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int 2009;76:614-21.
74. Perianayagam A, Sterns RH, Silver SM, Grieff M, Mayo R, Hix J et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008;3:331-6.
75. Gankam-Kengne F, Soupart A, Pochet R, Brion JP, Decaux G. Minocycline protects against neurologic complications of rapid correction of hyponatremia. J Am Soc Nephrol;21:2099-108.
76. Hoorn EJ, Zietse R. Vasopressin-receptor antagonists. Future Cardiol 2010;6:523-34.
77. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001;51:372-90. (Pubitemid 32718586)
78. Verbalis JG. Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002;29:1-9.
79. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Brunton L, Lazo JS, Parker KL, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2006. p. 771-88.
80. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-32. (Pubitemid 351626846)
81. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006;69:2124-30. (Pubitemid 43882098)
82. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112. (Pubitemid 44749318)
83. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-12.
84. Konstam MA, Gheorghiade M, Burnett JC, Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31. (Pubitemid 46513233)
85. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43. (Pubitemid 46513234)
86. Pang PS, Gheorghiade M, Dihu J, et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. Am Heart J 2011;161:1067-72.
87. P Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009;30:2233-40.
88. Gerbes AL, Gulberg V, Cines P, Decaux G, Gross P, Gandjini H et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124:933-9. (Pubitemid 36389796)
89. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008;48:204-13. (Pubitemid 351975545)